Rivastigmine Patch Compared to Melatonin Patch in Prevention of Postoperative Delirium
Primary Purpose
Delirium
Status
Completed
Phase
Phase 1
Locations
Egypt
Study Type
Interventional
Intervention
Rivastigmine Transdermal System [Exelon]
Melatonin
Sponsored by
About this trial
This is an interventional prevention trial for Delirium
Eligibility Criteria
Inclusion Criteria:
- American Society of Anaesthesiologists physical status I-III,
- Aged 60-85 years old,
- Undergoing major orthopaedic surgery
Exclusion Criteria:
- History of CNS disorders, such as brain injury, stroke; mental illness; dementia
- Metabolic disorders and electrolyte disturbances
- Alcohol or drug dependence
- Secondary surgery or severe infectious complications
- Severe sensory impairment causing difficulty in communication (deafness or blindness)
- Medications affecting CNS as (Antipsychotics, Anticonvulsants, Antiparkinsonian, Antidepressants)
Sites / Locations
- Ain Shams University
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Group R: patients receive Rivastigmine patch
Group M: patients receive Melatonin patch
Arm Description
receive a Rivastigmine patch (4.6 mg) 24 h before the operation to 3 days post-operative
receive Melatonin patch (7 mg) 24 h before the operation to 3 days post-operative
Outcomes
Primary Outcome Measures
compare between the two groups regarding the incidence of developing Delirium among the elderly patients
incidence of developing postoperative delirium by Confusion Assessment Method which consisting of four features: it indicate delirium if features 1 and 2 are present and either feature 3 or 4 is present.
Secondary Outcome Measures
compare between both groups regarding level of sedation
level of sedation by Ramsy Sedation Score which consists of 6 points: score 1; patient is Anxious (not sedated), 6; No response to stimulus (deeply sedated)
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04189666
Brief Title
Rivastigmine Patch Compared to Melatonin Patch in Prevention of Postoperative Delirium
Official Title
Rivastigmine Patch (Exelon Patch) Compared to Melatonin Patch in Prevention of Postoperative Delirium in Elderly
Study Type
Interventional
2. Study Status
Record Verification Date
July 2020
Overall Recruitment Status
Completed
Study Start Date
November 18, 2019 (Actual)
Primary Completion Date
April 10, 2020 (Actual)
Study Completion Date
May 1, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ain Shams University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
5. Study Description
Brief Summary
180 patients will be randomly divided into two groups 90 patients each using a computer-generated program.
Group R: 90 patients will receive a Rivastigmine patch (4.6 mg) 24 h before the operation to 3 days post-operative Group M: 90 patients will receive Melatonin patch (7 mg) 24 h before the operation to 3 days post-operative Patients in the two groups will be compared regarding incidence and severity of delirium on postoperative days 1, 2 or 3 and 7
Detailed Description
180 elderly patients American Society of Anaesthesiologists physical status I-III aged 60-85 years old undergoing major orthopaedic surgery will be included in this study The day prior to the operation all patients will be examined by an anaesthesia resident ''who is blinded to the study'' for preoperative cognitive impairment using Confusion Assessment Method. Patients with delirium were excluded from the study The 180 patients will be randomly divided into two groups 90 patients each using a computer-generated program. The patches will be given to the ward nurse who is blinded to the study to be administered to the patient 24 hours preoperative, during the operation and 3 days postoperative Group R: 90 patients will receive a Rivastigmine patch (4.6 mg) 24 h before the operation to 3 days post-operative Group M: 90 patients will receive Melatonin patch (7 mg) 24 h before the operation to 3 days post-operative On the day of the operation, patients will not receive premedication. In the operating room basic monitoring in the form of NIBP, SBP (systolic blood pressure), DBP (diastolic blood pressure), SPO2 (pulse oxygen saturation), ECG (electrocardiogram), will be attached and recorded every 30 mins. Level of intraoperative sedation will be monitored using Ramsay Sedation Scale.
Patients of both groups will receive Regional anaesthesia in the form of spinal or epidural anaesthesia according to Anaesthesia and surgical team preference and according to each case. Patient will be put in the sitting position, back will be sterilized by povidone- iodine, drapes will cover the back of the patient, L4-L5 or L3-L4 level will be palpated and local anaesthetic in the form of 1 ml of 2% lidocaine will be injected subcutaneous In case of spinal anaesthesia; a spinal needle G25 will be introduced. After appearance of CSF, heavy Marcaine will be injected intrathecally.
In case of epidural anaesthesia; a Tuohy needle will be introduced, on feeling loss of resistance a catheter will be threaded upward, secured in place, a test dose of 3 ml 2% lidocaine will be injected, then 12-18 ml of 0.5% isobaric Marcaine will be injected After completing the surgery patients will be sent to the Surgical ICU for postoperative monitoring. basic monitoring in the form of (NIBP, SPO2, ECG) will be monitored continuously and any abnormality will be recorded and managed according to the ICU protocol. All patients will be examined by the same anaesthesia resident ''who is blinded to the study'' for PD using Confusion Assessment Method (CAM) and level of sedation using RSS on the first, second, third and 7th postoperative day and for those who develop PD a CAM-S score will be done to assess the severity of PD.
And patients with delirium will be followed up and managed properly by a Neurology specialist.
Patients in the two groups will be compared regarding incidence and severity of delirium on postoperative days 1, 2 or 3 and 7 The investigator's primary outcome is to compare between the two groups regarding the incidence of developing PD among the elderly patients The secondary outcome is to compare between both groups regarding the severity of PD and level of sedation
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Delirium
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
180 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Group R: patients receive Rivastigmine patch
Arm Type
Active Comparator
Arm Description
receive a Rivastigmine patch (4.6 mg) 24 h before the operation to 3 days post-operative
Arm Title
Group M: patients receive Melatonin patch
Arm Type
Active Comparator
Arm Description
receive Melatonin patch (7 mg) 24 h before the operation to 3 days post-operative
Intervention Type
Drug
Intervention Name(s)
Rivastigmine Transdermal System [Exelon]
Other Intervention Name(s)
Exelon
Intervention Description
compare the ability of the drug in preventing postoperative delirium
Intervention Type
Drug
Intervention Name(s)
Melatonin
Other Intervention Name(s)
melatonin patch
Intervention Description
compare the ability of the drug in preventing postoperative delirium
Primary Outcome Measure Information:
Title
compare between the two groups regarding the incidence of developing Delirium among the elderly patients
Description
incidence of developing postoperative delirium by Confusion Assessment Method which consisting of four features: it indicate delirium if features 1 and 2 are present and either feature 3 or 4 is present.
Time Frame
seventh postoperative day
Secondary Outcome Measure Information:
Title
compare between both groups regarding level of sedation
Description
level of sedation by Ramsy Sedation Score which consists of 6 points: score 1; patient is Anxious (not sedated), 6; No response to stimulus (deeply sedated)
Time Frame
seventh postoperative day
10. Eligibility
Sex
All
Minimum Age & Unit of Time
60 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
American Society of Anaesthesiologists physical status I-III,
Aged 60-85 years old,
Undergoing major orthopaedic surgery
Exclusion Criteria:
History of CNS disorders, such as brain injury, stroke; mental illness; dementia
Metabolic disorders and electrolyte disturbances
Alcohol or drug dependence
Secondary surgery or severe infectious complications
Severe sensory impairment causing difficulty in communication (deafness or blindness)
Medications affecting CNS as (Antipsychotics, Anticonvulsants, Antiparkinsonian, Antidepressants)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rania Hussien, MD
Organizational Affiliation
lLecturer of Anaesthesia, Ain Shams University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ain Shams University
City
Cairo
State/Province
Abassia
Country
Egypt
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Rivastigmine Patch Compared to Melatonin Patch in Prevention of Postoperative Delirium
We'll reach out to this number within 24 hrs